How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

The Global Board of Advisors (GBA) consists of prominent individuals, including business leaders, noted academics, and former government officials from developed and emerging-market countries. The ...

At the University of Bristol, our vision is ambitious and bold. Our course explores power, who exercises it, for whom, how it is distributed, and with what consequences. You will gain insight into the ...

Your institution does not have access to this book on JSTOR. Try searching on JSTOR for other items related to this book. https://doi.org/10.2307/j.ctvjnrt76.5 https ...

Climate policies are increasingly politicized, and decisions often do not survive changes in government. This undermines international climate agreements, as effective governance requires ...

Every geopolitical event — a war, an election, a new tariff, a technological breakthrough — sends ripples through the global economy. On The Spillover, Sebastian Mallaby and Rebecca Patterson trace ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...